Parexel

Parexel is a comprehensive CRO offering end-to-end biopharmaceutical development services spanning portfolio optimization, early development, integrated clinical development, regulatory approval, and lifecycle value substantiation. The organization delivers Phase I–IV clinical trials with integrated strategies for safety, data integrity, and regulatory compliance. Key service areas include quantitative clinical pharmacology and model-informed drug development (MIDD), real-world evidence generation, biomarker and genomic medicine strategy, medical communications, drug safety and pharmacovigilance, and market access consulting. Parexel maintains therapeutic expertise across neuroscience, general medicine, infectious disease and vaccines, immunology, oncology, hematology, ophthalmology, and cross-therapeutic areas including cell and gene therapies, pediatrics, and rare diseases. The organization operates a proprietary AI-enabled clinical development suite (ParexelAI) to accelerate patient outcomes. Parexel employs former regulators and HTA professionals to provide tailored regulatory and compliance strategies. The company maintains a global site network and operates functional service provider (FSP) delivery models in clinical trials.